Consensus Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 07:00:00 29/10/26 am AEDT			5-day change	1st Jan Change
529.69 ^USD	+1.66%		+0.99%	+16.84%

29/10	ConvaTec to Spend GBP500 Million on New Global R&D Hub in Manchester, England, Over Next Decade	MT
24/10	Vertex Pharmaceuticals Incorporated Presents at American Society of Nephrology Kidney Week 2026, Oct-23-2026 06:15 PM

Evolution of the Average Target: Vertex Pharmaceuticals Incorporated

Evolution of the Target Price: Vertex Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated

cd70366e656c8533e8.MScikZDnEsYErtK5GPAGaUtk0FnsYCBdEueuIGVh5iE.WGV6pPysR5xj6JvXV6JWPDIdpRWiNHgQfYnvTigN1BNTEVLD4ot8pX7Hgw~c52d45e51dd6cb67d877a109a8acdf77

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

23/10	5 Healthcare Stocks to Watch as Investors Look Beyond Big Tech
15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
08/10	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
03/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
13/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
11/08	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
11/08	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
06/08	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
05/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
05/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
04/08	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
04/08	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
04/08	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
04/08	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
04/08	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
04/08	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
04/08	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
21/07	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
20/07	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
14/07	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
10/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
08/07	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERTEX PHARMACEUTICALS INCORPORATED					+9.68%
	ELI LILLY AND COMPANY					+4.04%
	JOHNSON & JOHNSON					+3.97%
	ABBVIE INC.					-1.12%
	ROCHE HOLDING AG					-3%
	MERCK & CO., INC.					+12.65%
	NOVARTIS AG					-3.77%
	ASTRAZENECA PLC					+23.18%
	AMGEN INC.					-11.3%
	GILEAD SCIENCES, INC.					+0.7%
	Average					+3.50%
	Weighted average by Cap.					+3.27%